Recombinant multi-species BCL10 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine BCL10 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
This gene was identified by its translocation in a case of mucosa-associated lymphoid tissue (MALT) lymphoma. The protein encoded by this gene contains a caspase recruitment domain (CARD), and has been shown to induce apoptosis and to activate NF-kappaB. This protein is reported to interact with other CARD domain containing proteins including CARD9, 10, 11 and 14, which are thought to function as upstream regulators in NF-kappaB signaling. This protein is found to form a complex with MALT1, a protein encoded by another gene known to be translocated in MALT lymphoma. MALT1 and this protein are thought to synergize in the activation of NF-kappaB, and the deregulation of either of them may contribute to the same pathogenetic process that leads to the malignancy. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Mar 2016]
The Alternative Names of target: B-cell CLL/lymphoma 10 (Bcl-10),B-cell lymphoma/leukemia 10,BCL-10,BCL10,Bcl10,CARD-containing molecule enhancing NF-kappa-B,CARD-like apoptotic protein (hCLAP),CARMEN,CED-3/ICH-1 prodomain homologous E10-like regulator (CIPER),CIPER,CLAP,Cellular homolog of vCARMEN (cCARMEN),Cellular-E10 (c-E10),IMD37,ME10,Mammalian CARD-containing adapter molecule E10 (mE10),c-E10,cE10,mE10
Go
to BCL10 products collection
>>
(antibodies,
antigen, VLP, mRNA, ORF viral vector, etc)
Product information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-IP13325-Ag-1/ GM-Tg-hg-IP13325-Ag-2 | Human BCL10 protein | Human |
| GM-Tg-rg-IP13325-Ag-1/ GM-Tg-rg-IP13325-Ag-2 | Rat BCL10 protein | Rat |
| GM-Tg-mg-IP13325-Ag-1/ GM-Tg-mg-IP13325-Ag-2 | Mouse BCL10 protein | Mouse |
| GM-Tg-cynog-IP13325-Ag-1/ GM-Tg-cynog-IP13325-Ag-2 | Cynomolgus/Rhesus macaque BCL10 protein | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-IP13325-Ag-1/ GM-Tg-felg-IP13325-Ag-2 | Feline BCL10 protein | Feline |
| GM-Tg-cang-IP13325-Ag-1/ GM-Tg-cang-IP13325-Ag-2 | Canine BCL10 protein | Canine |
| GM-Tg-bovg-IP13325-Ag-1/ GM-Tg-bovg-IP13325-Ag-2 | Bovine BCL10 protein | Bovine |
| GM-Tg-equg-IP13325-Ag-1/ GM-Tg-equg-IP13325-Ag-2 | Equine BCL10 protein | Equine |
Size: 1mg | 10mg | 100mg
Product Description
| Catalog No. |
GM-Tg-hg-IP13325-Ag-1/ GM-Tg-hg-IP13325-Ag-2;
GM-Tg-rg-IP13325-Ag-1/ GM-Tg-rg-IP13325-Ag-2;
GM-Tg-mg-IP13325-Ag-1/ GM-Tg-mg-IP13325-Ag-2; GM-Tg-cynog-IP13325-Ag-1/ GM-Tg-cynog-IP13325-Ag-2; GM-Tg-felg-IP13325-Ag-1/ GM-Tg-felg-IP13325-Ag-2; GM-Tg-cang-IP13325-Ag-1/ GM-Tg-cang-IP13325-Ag-2; GM-Tg-bovg-IP13325-Ag-1/ GM-Tg-bovg-IP13325-Ag-2; GM-Tg-equg-IP13325-Ag-1/ GM-Tg-equg-IP13325-Ag-2 |
| Products Name | BCL10 protein |
| Species | Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine |
| Target Name | BCL10 |
| Protein Sub-location | Introcelluar Protein |
| Isotypes | Recombinant protein |
| Expression platform | Mammalian cell |
| Bioactivity validation | Affintiy&bioactivity validated by ELISA, cell culture validated. |
| Tag | His |
| Products description | Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine BCL10 protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution |
Lyophilized from GM's Protein Stability Buffer2
(PSB2,Confidential Ingredients) or PBS
(pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
About Gmab

GMab, developed by GeneMedi, constitutes an
advanced library of recombinant
monoclonal antibodies, each meticulously
designed to target specific molecular
entities. Leveraging the sophisticated
capabilities of GM’s Taurus™ and LIBRA™
platforms, GMab synthesizes antibodies
characterized by high binding affinity,
exceptional physicochemical stability, and
optimal developability profiles.
Through
expression in mammalian cell lines, GMab has
been established as a paradigmatic
reference antibody. It holds significance in
myriad domains of biological drug
discovery, encompassing cellular cultivation,
innovative assay methodologies,
strategic animal model systematization, in-depth
pharmacokinetic & pharmacodynamic
(PK/PD) modeling, and intricate mechanism of
action (MOA) investigations.